Status:

UNKNOWN

RCA for CRRT in Liver Failure and High Risk Bleeding Patients

Lead Sponsor:

Air Force Military Medical University, China

Conditions:

Liver Failure

Eligibility:

All Genders

18+ years

Phase:

NA

Brief Summary

The purpose of this single center, randomized, control, open-labeled study is to evaluate the effect and safety of RCA versus no anticoagulation for CRRT in patients with liver failure and high risk b...

Detailed Description

Liver failure (LF) is a common co-morbidity in critical care patients who need continuous renal replacement therapy (CRRT). Patients with LF are usually associated with impaired coagulation, impaired ...

Eligibility Criteria

Inclusion

  • Liver failure (acute liver failure and chronic liver failure)
  • High bleeding risk
  • Scheduled CRRT treatment
  • Informed consent

Exclusion

  • Use of other anticoagulants
  • Uncorrectable hypoxemia (PaO2 \< 60 mmHg) or systemic hypoperfusion shock
  • Pregnancy or lactation
  • Fistula, CRRT treatment time \< 12 hours

Key Trial Info

Start Date :

September 6 2018

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

August 30 2021

Estimated Enrollment :

90 Patients enrolled

Trial Details

Trial ID

NCT03791190

Start Date

September 6 2018

End Date

August 30 2021

Last Update

January 3 2019

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Xijing Hospital of Nephrology

Xi'an, Shaanxi, China, 710032

RCA for CRRT in Liver Failure and High Risk Bleeding Patients | DecenTrialz